Bart Deplancke graduated as a Biochemical Engineer at Ghent University (Belgium, 1998) after which he pursued doctoral studies in Immunobiology at the University of Illinois (USA) and postdoctoral work in regulatory genomics at the Harvard and UMass Medical Schools. In 2007, he established his lab at the EPFL School of Life Sciences where he is now Full Professor and Vice-Dean of Innovation and is developing new experimental and computational approaches to study the biology of the genome. The Deplancke Lab has by now built a sizeable toolkit, involving microfluidics, high-throughput sequencing, and single cell genomics, to address questions pertaining to the origin, diversity and function of stromal cells in adipose tissue as well as to how genomic variation affects molecular and organismal diversity with a specific focus on metabolic phenotypes. In 2013, he became a Swiss Institute of Bioinformatics Group Leader and in 2017 was elected to the National Research Council of the Swiss National Science Foundation. He is also the co-founder of two Biotech companies (Genohm, Acquired by Agilent in 2018; and Alithea Genomics).